Latest News

Atomo Diagnostics (ASX:AT1) has completed a share placement and says it will implement changes to its board and business operations to reflect its strategic and operational needs.

Cell therapy company Chimeric Therapeutics (ASX:CHM) recently announced the investor participation in a non-renounceable entitlement offer to raise up to $3.2 million.

Regenerative medicine company Orthocell (ASX:OCC) has appointed its first four US distributors of its nerve repair product Remplir.

Lumos Diagnostics (ASX:LDX) has announced that it has received confirmation of reimbursement coverage from two additional Medicare Administrative Contractors (MACS), First Coast Service Options and Noridian Healthcare Solutions.

Allogeneic cell therapy company Mesoblast (ASX:MSB) has announced expanded US payer coverage for its Ryoncil (remestemcel-L), the first mesenchymal stromal cell therapy approved by the US FDA.

Anatara Lifesciences (ASX:ANR) has updated investors on an analysis following the completion of Stage 2 of its GaRP-IBS (Irritable Bowel Syndrome) trial.

Clinical-stage company Neurizon Therapeutics (ASX:NUZ) has announced the appointment of Dan O’Connell as chief financial officer.

Recce Pharmaceuticals (ASX:RCE) has received Human Research Ethics Approval (HREC) to enrol up to 20 additional patients with Diabetic Foot Infections in its Phase 2 trial of R327G.

Race Oncology (ASX:RAC) has announced the activation of the second site for patient enrolment for its Phase 1 clinical trial of RC220 (bisantrene), combined with doxorubicin, in patients with advanced solid tumours.

The company said it plans the commercial launch of the Vision-MR Ablation Catheter and the new AdvantageMR system in June across new and existing sites in Europe.

Telix Pharmaceuticals (ASX:TLX) has announced that preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent high-grade glioma support the patient benefit seen in the IPAX-1 study.

Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has announced the US FDA has granted PTX-100 a Fast Track Designation for the treatment of adults with relapsed or refractory mycosis fungoides, the most common subtype of Cutaneous T Cell Lymphoma.